What Lu-177 DOTATATE Targets
Many neuroendocrine tumour (NET) cells carry somatostatin receptors on their surface. Lu-177 DOTATATE is a molecule that binds to these receptors. It consists of a somatostatin analogue (DOTATATE) linked to the radioactive isotope Lutetium-177. When injected, it circulates through the body, finds cells expressing somatostatin receptors, attaches to them, and delivers targeted beta radiation.
The radiation has a range of only a few millimetres, which means it primarily affects the cells it has bound to while minimising damage to nearby healthy tissue. This targeted mechanism is what makes Lu-177 DOTATATE therapy different from conventional chemotherapy, which affects cells throughout the body.
Who Qualifies for This Treatment?
The most important requirement is that the tumour must express somatostatin receptors. This is confirmed by a somatostatin receptor PET CT scan, such as a Ga-68 DOTANOC or Ga-68 DOTATATE PET CT. If the scan shows good uptake of the tracer at the tumour sites, it indicates that the cancer cells carry the receptors needed for the therapy to work.
Beyond the scan result, the treating team assesses kidney function, blood cell counts, liver function, and overall health status. Adequate kidney function is particularly important because the kidneys help clear the radioligand from the body. Patients with severely reduced kidney function may not be able to receive the treatment safely.
Lu-177 DOTATATE therapy is typically considered for patients with advanced or metastatic NETs that are progressing despite other treatments such as somatostatin analogues (octreotide or lanreotide). In some cases, it may be used earlier in the treatment pathway.
The Treatment Process
Treatment is given as an intravenous infusion in a controlled nuclear medicine setting. An amino acid solution is usually co-administered during the infusion to protect the kidneys from absorbing too much radiation. The infusion itself takes approximately 30 to 60 minutes, but the entire session, including the kidney protection infusion, may last several hours.
The standard protocol involves four treatment cycles, with each cycle separated by approximately 8 weeks. However, the number and spacing of cycles can vary depending on the patient’s response and tolerance.
Monitoring Between Cycles
Between treatment cycles, regular blood tests are performed to check kidney function and blood cell counts. Imaging may also be performed to assess the tumour response. If blood counts drop below safe levels, the next cycle may be delayed until they recover.
Possible Side Effects
The most common side effects include nausea (usually managed with anti-nausea medication given during the infusion), fatigue, and temporary decreases in blood cell counts. Some patients experience abdominal discomfort.
Because the kidneys are involved in clearing the radioligand, kidney protection during each infusion is standard practice. Serious kidney damage is uncommon when this precaution is taken.
Bone marrow suppression (reduced blood cell production) can occur, particularly after multiple cycles. This is monitored through regular blood tests, and treatment is adjusted if needed.
What Results Can Patients Expect?
Clinical studies have shown that Lu-177 DOTATATE therapy can slow or stabilise tumour growth in many patients with somatostatin receptor-positive NETs. Some patients experience tumour shrinkage. The treatment has also been associated with improvements in quality of life and symptom control, particularly for patients with hormone-producing NETs that cause symptoms like flushing or diarrhoea.
Response varies between patients, and the therapy does not work for everyone. Your treating team will monitor your progress and discuss the results with you after each cycle and through follow-up imaging.
If you have been diagnosed with a neuroendocrine tumour, discuss with your oncologist whether somatostatin receptor imaging and Lu-177 DOTATATE therapy could be relevant to your treatment plan.